37,202 Bristol Myers Squibb Company $BMY Shares Bought by Meeder Asset Management Inc.

Meeder Asset Management Inc. increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 182.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 57,628 shares of the biopharmaceutical company’s stock after purchasing an additional 37,202 shares during the period. Meeder Asset Management Inc.’s holdings in Bristol Myers Squibb were worth $3,596,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. State Street Corp boosted its holdings in Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares during the period. Primecap Management Co. CA bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Bristol Myers Squibb by 0.5% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after purchasing an additional 119,690 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth $980,862,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling at Bristol Myers Squibb

In other news, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BMY. Leerink Partners cut shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $73.00 to $59.00 in a research note on Monday, October 5th. Roth Capital began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target on the stock. Morgan Stanley cut their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a report on Friday, October 30th. Wells Fargo & Company decreased their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 13th. Finally, Rothschild & Co Redburn boosted their price objective on Bristol Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $65.46.

Get Our Latest Stock Analysis on Bristol Myers Squibb

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $58.64 on Thursday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The stock has a fifty day moving average price of $61.65 and a two-hundred day moving average price of $60.41. Bristol Myers Squibb Company has a 52-week low of $45.26 and a 52-week high of $68.64. The firm has a market capitalization of $119.87 billion, a P/E ratio of 12.95, a P/E/G ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.63 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.46 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s payout ratio is presently 55.88%.

More Bristol Myers Squibb News

Investors following BMY have been watching these news items:

  • Positive Sentiment: Phase 3 ADEPT program results showed that KarXT reduced psychosis symptoms, including hallucinations and delusions, in people with Alzheimer’s disease. The findings add potential to BMS’s pipeline, although the reported data are preliminary. Reuters article on KarXT results
  • Negative Sentiment: BMY shares broke below their 200-day moving average, a technical signal that can weigh on investor sentiment and raise concerns about near-term momentum. Article on BMY’s moving-average break
  • Negative Sentiment: A comparison by Zacks argued that Merck currently offers a stronger investment case, citing its stock performance, oncology position, pipeline expansion and growth drivers. This is an analyst opinion rather than a change to BMS’s fundamentals, but it may add to relative-investment concerns. Zacks comparison of Bristol Myers and Merck

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Further Reading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.